Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 10:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 1,668 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Comparator Clear all
Active, not recruiting Phase 3 Interventional

A Study of TLC590 for Postsurgical Pain Following Bunionectomy

NCT07222748
View directory record Official record
Conditions
Postoperative Pain
Interventions
TLC590, Liposomal Bupivacaine, Saline Placebo
Drug
Lead sponsor
TLC Biopharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
Miami, Florida • Bellaire, Texas • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 20, 2026, 10:06 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT03370133
View directory record Official record
Conditions
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis
Interventions
Bimekizumab, Ustekinumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
25
States / cities
Phoenix, Arizona • Bakersfield, California • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 20, 2026, 10:06 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Oxytocin and Brain Responses in Maternal Addiction

NCT02979093
View directory record Official record
Conditions
Maternal Behavior, Maternal Addiction
Interventions
Oxytocin, Placebos, Functional MRI scanning
Drug · Procedure
Lead sponsor
Lane Strathearn, MBBS PhD
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
2
States / cities
New Haven, Connecticut • Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Oct 20, 2026, 10:06 PM EDT
Completed Phase 2 Interventional

Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women

NCT03475706
View directory record Official record
Conditions
Overactive Bladder
Interventions
Solabegron immediate release tablets, low dose, Solabegron immediate release tablets, high dose, Matching Placebo
Drug
Lead sponsor
Velicept Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
86
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Mobile, Alabama + 77 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 20, 2026, 10:06 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study to Evaluate the Efficacy and Safety of JointStem in Treatment of Osteoarthritis

NCT02674399
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
JointStem, Synvisc-One
Drug
Lead sponsor
Nature Cell Co. Ltd.
Industry
Eligibility
22 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Santa Monica, California • Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Oct 20, 2026, 10:06 PM EDT
Completed Phase 3 Interventional

Efficacy Study of Pioglitazone and Glimepiride on the Rate of Progression of Atherosclerotic Disease.

NCT00225264
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Pioglitazone, Glimepiride
Drug
Lead sponsor
Takeda
Industry
Eligibility
45 Years to 85 Years
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Oct 20, 2026, 10:06 PM EDT
Completed Phase 2Phase 3 Interventional

Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Community Acquired Bacterial Pneumonia (CABP)

NCT01530763
View directory record Official record
Conditions
Infections, Community Acquired Pneumonia
Interventions
Ceftaroline fosamil, Ceftriaxone, amoxicillin clavulanate
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
2 Months to 18 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Long Beach, California • Oakland, California • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2015 · Synced Oct 20, 2026, 10:06 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Depression & Other Neuropsychiatric Symptoms After Traumatic Brain Injury (TBI)

NCT02367521
View directory record Official record
Conditions
TBI Depression
Interventions
Low Frequency Right sided repetitive transcranial magnetic stimulation (LFR rTMS), Sham Comparator: Sham Treatment
Combination Product · Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 20, 2026, 10:06 PM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate Armodafinil Treatment in Improving Prefrontal Cortical Activation and Working Memory Performance

NCT00711516
View directory record Official record
Conditions
Excessive Sleepiness
Interventions
Armodafinil, Placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
9
States / cities
Burlingame, California • San Diego, California • Stanford, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Oct 20, 2026, 10:06 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis

NCT06878404
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Icotrokinra, Placebo, Active reference comparator
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
9
States / cities
Jonesboro, Arkansas • DeBary, Florida • Plantation, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 20, 2026, 10:06 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)

NCT06220604
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
JNJ-77242113, JNJ-77242113 Matching Placebo, Deucravacitinib, Deucravacitinib Matching Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
731 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
37
States / cities
Phoenix, Arizona • Encinitas, California • Encino, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 20, 2026, 10:06 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis

NCT02045277
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
IDP-118 Lotion, IDP-118 Monad HP Lotion, IDP-118 Monad Taz Lotion, IDP-118 Vehicle Lotion
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
18
States / cities
Encino, California • San Diego, California • Santa Rosa, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Oct 20, 2026, 10:06 PM EDT
Active, not recruiting Phase 3 Interventional

Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy

NCT04083339
View directory record Official record
Conditions
Diabetic Cardiomyopathies
Interventions
AT-001, Placebo
Drug
Lead sponsor
Applied Therapeutics, Inc.
Industry
Eligibility
40 Years and older
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
28
States / cities
Beverly Hills, California • La Jolla, California • Lincoln, California + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Oct 20, 2026, 10:06 PM EDT
Active, not recruiting Not applicable Interventional

Improving Cardiac Rehabilitation Exercise Using Target Heart Rate Trial

NCT05925634
View directory record Official record
Conditions
Myocardial Infarction, Coronary Artery Bypass, Percutaneous Coronary Intervention, Heart Failure, Cardiac Valve Surgery
Interventions
RPE (usual care), GXT+THHR (intervention)
Behavioral
Lead sponsor
Baystate Medical Center
Other
Eligibility
60 Years to 99 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Springfield, Massachusetts • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 20, 2026, 10:06 PM EDT
Completed Phase 2 Interventional Results available

A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole

NCT05055128
View directory record Official record
Conditions
Erosive Esophagitis
Interventions
X842, X842 Dummy, Lansoprazole, Lansoprazole Dummy
Drug
Lead sponsor
Cinclus Pharma Holding AB
Industry
Eligibility
18 Years to 75 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 20, 2026, 10:06 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study to Examine the Effects of Minocycline Extended-Release Tablets on Sperm Production in Human Males.

NCT00765336
View directory record Official record
Conditions
Human Volunteer
Interventions
minocycline extended release, Placebo
Drug
Lead sponsor
Medicis Pharmaceutical Corporation
Industry
Eligibility
18 Years and older · Male only
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
10
States / cities
Tarzana, California • Minneapolis, Minnesota • Lawrenceville, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2011 · Synced Oct 20, 2026, 10:06 PM EDT
Active, not recruiting No phase listed Observational

Real-World Data Study of Troriluzole-Treated Patients With Spinocerebellar Ataxia (SCA) Compared to a Matched Natural History Control

NCT06529146
View directory record Official record
Conditions
Spinocerebellar Ataxias
Interventions
BHV-4157
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
909 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 20, 2026, 10:06 PM EDT
Completed Phase 2 Interventional

Vitamin D3 Supplementation for Heart Failure Patients

NCT01636570
View directory record Official record
Conditions
Heart Failure, Vitamin D Deficiency, Cardiomyopathy, Congestive Heart Failure
Interventions
Placebo Comparator: Sugar Pill, Vitamin D3 (cholecalciferol)
Drug
Lead sponsor
Heidi Moretti, MS, RD
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Missoula, Montana
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 20, 2026, 10:06 PM EDT
Completed Phase 2 Interventional Results available

Randomized Placebo Controlled Study to Determine Safety, Pharmacodynamics and Efficacy of ILV-094 in Atopic Dermatitis

NCT01941537
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
ILV-094, Placebo Comparator
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Oct 20, 2026, 10:06 PM EDT
Completed Phase 2 Interventional Results available

Celecoxib as a Post-tonsillectomy Pain Medication

NCT00583453
View directory record Official record
Conditions
Tonsillitis
Interventions
Celecoxib, Placebo
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 20, 2026, 10:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intra Oral Application (IOA) Testing Study of a Stannous Toothpaste

NCT07419672
View directory record Official record
Conditions
Dental Caries
Interventions
Negative Control Treatment Slurry (Fluoride-Free), Active Comparator Fluoride Treatment (0.454% SnF), Test Fluoride Treatment (0.454% SnF) (Investigational Toothpaste)
Drug
Lead sponsor
Church & Dwight Company, Inc.
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Noblesville, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 20, 2026, 10:06 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Reducing HIV: Safer Sex Skill Building in Pregnant Drug Abusing Women

NCT00619320
View directory record Official record
Conditions
HIV Infections, Substance Use
Interventions
Safer Sex Skills Building (SSB)
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older · Female only
Enrollment
380 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
2
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 12, 2013 · Synced Oct 20, 2026, 10:06 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Equivalence of Estradiol Vaginal Cream to Reference Standard in the Treatment of Vaginal Atrophy

NCT03332303
View directory record Official record
Conditions
Vulvar and Vaginal Atrophy
Interventions
Estrace® Cream, Estradiol Vaginal Cream, Vehicle Cream
Drug
Lead sponsor
Prasco LLC
Industry
Eligibility
30 Years to 75 Years · Female only
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
27
States / cities
Sacramento, California • San Diego, California • Denver, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated May 30, 2024 · Synced Oct 20, 2026, 10:06 PM EDT
Completed Phase 3 Interventional

Diclofenac Patch for Treatment of Acute Pain Due to Mild to Moderate Soft Tissue Injuries (TAPED)

NCT00931866
View directory record Official record
Conditions
Acute Pain, Soft Tissue Injury
Interventions
Diclofenac Sodium, Matching Placebo Patch
Drug
Lead sponsor
Cerimon Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 16, 2010 · Synced Oct 20, 2026, 10:06 PM EDT